Chemed Raises FY24 EPS From $23.30-$23.70 To $23.55-$23.80 Vs $23.21 Est.
Portfolio Pulse from Benzinga Newsdesk
Chemed Corporation has raised its FY24 EPS guidance from $23.30-$23.70 to $23.55-$23.80, surpassing the $23.21 estimate. VITAS is expected to see significant revenue and ADC growth, while Roto-Rooter is forecasted to experience a revenue decline. Covenant Health is projected to contribute positively to VITAS' revenue.
July 24, 2024 | 8:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chemed Corporation has raised its FY24 EPS guidance, indicating stronger-than-expected performance. VITAS is expected to see significant revenue growth, while Roto-Rooter faces a revenue decline. Covenant Health will positively impact VITAS' revenue.
The upward revision in EPS guidance suggests stronger-than-expected performance for Chemed. VITAS' significant revenue growth and positive contribution from Covenant Health are positive indicators. However, the revenue decline in Roto-Rooter may slightly offset these gains.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100